**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 74134

**Manuscript Type:** CASE REPORT

**Transplanted kidney loss during colorectal cancer chemotherapy: A case report**

Pośpiech M *et al*. Transplanted kidney loss during CRC chemotherapy

Marta Pośpiech, Aureliusz Kolonko, Teresa Nieszporek, Sylwia Kozak, Anna Kozaczka, Henryk Karkoszka, Mateusz Winder, Jerzy Chudek

**Marta Pośpiech, Sylwia Kozak, Jerzy Chudek,** Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia in Katowice, Katowice 40-027, Poland

**Aureliusz Kolonko, Henryk Karkoszka,** Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia in Katowice, Katowice 40-027, Poland

**Teresa Nieszporek,** Department of Nephrology, Transplantation and Internal Medicine, Mielecki Clinical Hospital of the Medical University of Silesia, Katowice 40-027, Poland

**Anna Kozaczka,** Department of Internal Diseases and Oncological Chemotherapy, Mielecki Clinical Hospital, Katowice 40-027, Poland

**Mateusz Winder,** Department of Radiology and Nuclear Medicine, Medical University of Silesia in Katowice, Katowice 40-752, Poland

**Author contributions:** Kozaczka A, Chudek J and Nieszporek T collected the clinical data; Pośpiech M and Kozak S designed the case report, reviewed the literature and drafted the manuscript; Karkoszka H performed and interpreted the kidney histology; Winder M prepared and interpreted the imaging; Chudek J and Kolonko A critically reviewed the manuscript; All authors read and approved the final manuscript.

**Corresponding author: Sylwia Kozak,** Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia in Katowice, Reymonta 8, Katowice 40-027, Poland. sylwiakozak@icloud.com

**Received:** December 14, 2021

**Revised:** March 2, 2022

**Accepted:** April 22, 2022

**Published online:** June 6, 2022

**ABSTRACT**

***BACKGROUND***

The overall risk of *de novo* malignancies in kidney transplant recipients (KTRs) is higher than that in the general population. It is associated with long-lasting exposure to immunosuppressive agents and impaired oncological vigilance due to chronic kidney disease. Colorectal cancer (CRC), frequently diagnosed in an advanced stage, is one of the most common malignancies in this cohort and is associated with poor prognosis. Still, because of the scarcity of data concerning adjuvant chemotherapy in this group, there are no clear guidelines for the specific management of the CRCs in KTRs. We present a patient who lost her transplanted kidney shortly after initiation of adjuvant chemotherapy for colon cancer.

***CASE SUMMARY***

A 36-year-old woman with a medical history of kidney transplantation (2005) because of end-stage kidney disease, secondary to chronic glomerular nephritis, and long-term immunosuppression was diagnosed with locally advanced pT4AN1BM0 (clinical stage III) colon adenocarcinoma G2. After right hemicolectomy, the patient was qualified to receive adjuvant chemotherapy that consisted of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4). The deterioration of kidney graft function after two cycles caused chemotherapy cessation and initiation of hemodialysis therapy after a few months. Shortly after that, the patient started palliative chemotherapy because of cancer recurrence with intraperitoneal spread.

***CONCLUSION***

Initiation of adjuvant chemotherapy for colon cancer increases the risk of rapid kidney graft loss driven also by under-immunosuppression.

**Key Words:** Kidney transplantation; Colorectal cancer; Adjuvant chemotherapy; Graft loss; Complications; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Pośpiech M, Kolonko A, Nieszporek T, Kozak S, Kozaczka A, Karkoszka H, Winder M, Chudek J. Transplanted kidney loss during colorectal cancer chemotherapy: A case report. *World J Clin Cases* 2022; 10(16): 6647-6655

**URL**: https://www.wjgnet.com/2307-8960/full/v10/i16/6647.htm

**DOI**: https://dx.doi.org/10.12998/wjcc.v10.i16.6647

**Core tip:** The occurrence of colorectal cancer (CRC) in kidney transplant recipients is higher than that in the general population. Advanced stage CRC is usually associated with poor outcome. Adjuvant chemotherapy may accelerate the graft loss after kidney transplant.

**INTRODUCTION**

Colorectal cancer (CRC) is one of the most common malignancies both in the general population[1] and in kidney transplant recipients (KTRs)[2,3]. The risk of CRC development is reported to be higher in transplant patients because of long-lasting exposure to immunosuppressive agents[4]. Although the patient survival rate for the KTR population with advanced CRC (stage III/IV) at the time of diagnosis is worse, mainly due to higher rates of recurrence, there was no significant difference in a 5-year patient survival in early cancer[5]. CRC in KTRs displays atypical characteristics in terms of tumor location, polyp size, and occurrence. The rate of ascending colon cancer is higher, whereas the rate of rectal cancer is lower in the transplant group[5,6]. Also, the number and size of polyps observed in preoperative colonoscopy are greater than in control patients. One of the possible causes of the poorer survival of KTRs with advanced cancer may be insufficient CRC treatment, *i.e.*, tendency to less frequent use of adjuvant chemotherapy [5,6] because of concerns associated with incompatibility with immunosuppression regimen and the risk of deterioration of kidney graft function. The above-mentioned obstacles preclude the formulation of clear guidelines for the management of CRC in KTRs.

Here, we present a patient with advanced colon cancer diagnosed 16 years after a successful kidney transplantation, presenting with an irreversible deterioration of kidney graft function shortly after the initiation of adjuvant CTH, to discuss the possible causes of kidney graft loss.

**CASE PRESENTATION**

***Chief complaints***

A 36-year-old woman with a medical history of kidney transplantation in 2005, after recent right hemicolectomy due to locally advanced pT4AN1BM0 (clinical stage III) colon adenocarcinoma (G2), was qualified (in March 2021) to adjuvant chemotherapy regimen based on oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4). At that time, the kidney graft function was satisfactory; however, the slow increase in serum creatinine up to 1.4 mg/dL was observed during the few preceding months. The blood tests showed anemia (hemoglobin, 8.4 g/dL), C-reactive protein 11.2 mg/L, CA-125 18.7 U/mL, and CEA 0.95 ng/mL. After two FOLFOX-4 cycles, substantial deterioration of kidney graft function was observed, resulting in the discontinuation of chemotherapy and return to hemodialysis.

***History of present illness***

In October 2020 (16 years post-transplant), the patient started to report recurrent mild abdominal pain without concomitant hematochezia, diarrhea, change in bowel motility, or weight loss. At the same time, a slight increase in serum creatinine from 1.0 to 1.4 mg/dL [estimated glomerular filtration rate (eGFR) 45 mL/min/1.73 m2], with no proteinuria, was detected. In January 2021, the patient was admitted to a surgery department with clinical suspicion of herniation of the terminal ileum into the cecum. During surgery, a large cecal tumor was found (7 cm × 5.5 cm × 5 cm), and a right hemicolectomy with terminal ileum–transverse colon graft was performed. Histological diagnosis was adenocarcinoma G2 invading the peritoneum and blood vessels, with metastases to two of 24 resected mesenteric lymph nodes (pT4AN1B) – corresponding to clinical stage III. A multidisciplinary team qualified the patient to adjuvant chemotherapy (FOLFOX-4), which was suspended due to abdominal wall abscess after the previous surgery. On March 17, 2021 (7 wk since hemicolectomy), the first FOLFOX-4 cycle was administered and the second was on April 1, 2021. However, the subsequent chemotherapy cycles were cancelled due to progressive kidney graft insufficiency. There was no deterioration of blood pressure control during CTH.

Meanwhile, immunosuppression was modified by conversion from mycophenolate mofetil 250 mg BID to everolimus 0.75 mg BID (Figure 1). Notably, during the subsequent 2 mo, the blood trough levels of everolimus were low (1.0–1.4 ng/mL). Finally, the drug was discontinued because of its poor gastric tolerance. In addition, the tacrolimus level started to fluctuate (with a nadir of 2.5 ng/mL), and *de novo* proteinuria was noticed up to 4.2 g/24 h. Lately, tacrolimus once daily was switched to twice daily formulation to achieve adequate blood trough levels. Serum creatinine level increased up to 3.4 mg/dL.

***History of past illness***

The patient was diagnosed with chronic glomerular nephritis at the age of 10 years. It was confirmed by kidney biopsy, and glucocorticoids and cyclophosphamide were initiated. In 2001, hepatitis C virus infection was diagnosed, and the patient underwent a successful 12-mo interferon-γ treatment. Hypertension was diagnosed at the age of 18 years in the course of chronic kidney disease. The patient developed end-stage kidney disease and started hemodialysis at the age of 19 years (2004). After 8 mo of dialysis therapy, the patient underwent kidney transplantation (2005) with basiliximab induction. The kidney graft function on an immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil and steroids was excellent, with serum creatinine of 1 mg/dL for many years. The immunosuppression schedule was modified between 4 and 8 years post-transplant by converting mycophenolate to azathioprine due to planned pregnancy. She passed two pregnancies, giving birth during 5 and 8 yearspost-transplant. During the whole observation, there were no episodes of acute kidney rejection or proteinuria. The blood trough levels of tacrolimus and mycophenolate mofetil were stable, at 6–7 ng/mL and 2.7 ng/mL, respectively.

***Personal and family history***

Family history was unremarkable.

***Physical examination***

Physical examination revealed no abnormalities except surgical scars.

***Laboratory examinations***

Because of the increase of serum creatinine up to 3.4 mg/dL, a kidney graft biopsy was performed on June 1, 2021. Histological examination revealed overlapping features of active chronic rejection and focal segmental glomerulosclerosis. Overall, interstitial fibrosis and tubular atrophy covered > 50% of the interstitial area (Figure 2). Donor-specific antigens were not present, whereas a moderate Epstein–Barr viremia (7485 copies/mL) was detected. Other virological results (hepatitis B virus, hepatitis C virus and cytomegalovirus) were negative at that time.

***Imaging examinations***

Computed tomography (CT) with contrast media administration was performed twice, during the oncological work-up, in June and September 2021. The second examination visualized intraperitoneal spread of colon adenocarcinoma, confirmed by positron emission tomography/CT (Figure 3), and corresponding with recent patient complaints about abdominal pain.

**FINAL DIAGNOSIS**

Active chronic rejection of transplanted kidney with features of recurrent glomerulonephritis and further intraperitoneal spread of colon cancer was also diagnosed.

**TREATMENT**

Hemodialysis therapy was initiated after creating an arteriovenous shunt when serum creatinine level exceeded 6 mg/dL. Before initiation of palliative chemotherapy, *KRAS*, *NRAS* and *BRAF* genotyping was performed. The analysis revealed mutation in codon 12 of the second exon (35 G>T) of *KRAS*, denoting resistance to anti-epidermal growth factor receptor therapy. FOLFOX-4 regimen was chosen as the first-line palliative chemotherapy due to early discontinuation of this regimen in the adjuvant setting, frequent intestinal toxicity of irinotecan in hemodialysis patients, and restriction in the reimbursement of bevacizumab in patients with chronic kidney disease.

**OUTCOME AND FOLLOW-UP**

The patient remains under the care of an oncologist and nephrologist, continuing hemodialysis and palliative chemotherapy. The timeline of the information presented in this case report is shown in Table 1.

**DISCUSSION**

Cancer is the second most common cause of mortality and morbidity in KTRs after cardiovascular disease[7]. This increased cancer risk in the KTR population is driven mainly by *de novo* cancers, with CRC being the third most common cause of cancer death after non-Hodgkin’s lymphoma and lung cancer[8]. CRC in KTRs is reported to have a worse 5-year survival rate than in the general population[9,10], and develops more often at a younger age[9-11]. Even so, our patient was diagnosed with an advanced CRC at the age of 36 years. However, an analysis of Australia and New Zealand Dialysis and Transplant Registry Data revealed that cancer rates in KTRs are similar to those in nontransplanted subjects 20–30 years older[12]. Still, it is noteworthy that there were some additional risk factors for such an early development of cancer in the given patient, except for the post-transplant immunosuppression. Firstly, the primary kidney disease was glomerulonephritis treated with steroids and cyclophosphamide, whereas the pretransplant immunosuppressive treatment was shown to increase the cancer risk[12,13]. Secondly, the use of azathioprine could be an independent risk factor for advanced colorectal neoplasia in KTRs[14]. The patient has received this medication for 5 years because of the planned conception. Thirdly, unlike the virus-related malignancies such as Kaposi’s sarcoma and cervical cancer, CRC used to develop late in the post-transplant observation[3], as in our case.

Nevertheless, when considering the undisputed tendency to the CRC development in younger KTRs in comparison to the general population, modified screening strategies were suggested in this specific cohort, including increased colonoscopy frequency[9] and early initial post-transplant colonoscopy within 2 years[10]. To date, KDIGO (Kidney Disease: Improving Global Outcomes) Guidelines suggested that screening for CRC should be performed as recommended for the general population[15]. A cost–benefit ratio is another issue, as it was shown that eight colonoscopies were needed to identify one case of advanced neoplasia in KTRs cohort older than 50 years[16]. Although some authors suggested that screening colonoscopy in KTRs should be expanded to include recipients younger than 50 years[11] or even between the age of 35 and 50 years[17], such a policy would be cost-ineffective, in contrast to a screening program with fecal hemoglobin testing[17]. However, the latter measure is characterized by poor sensitivity but reasonable specificity. Besides, a fecal hemoglobin concentration can be used to stratify probability for the detection of advanced colorectal neoplasia in individuals with positive fecal immunochemical test[18].

In KTRs diagnosed with cancer, treatment includes conventional approaches based on surgery, radiotherapy, and chemotherapy[7]. Such a complex treatment, often complicated by adverse reactions, is effective, even in advanced CRC cases[19]. Although the administration of adjuvant chemotherapy is a current standard of care in stage III colon cancer, the complication risk of such therapy is strongly recommended to be assessed, especially among patients with pre-existing kidney dysfunction[1]. The data concerning adjuvant and palliative chemotherapy and their outcomes in KTRs are limited (Table 2). Some advanced stage transplant patients did not receive adequate chemotherapy because of the concern of drug–drug interactions with the immunosuppressive regimen[20]. Despite that oxaliplatin and 5-fluorouracil are partly excreted in urine, the renal toxicity potential of anti-CRC drugs is low, except for *de novo* proteinuria and arterial thromboembolic events observed during bevacizumab therapy[20]. Nevertheless, oxaliplatin-based chemotherapy is neither nephrotoxic[21] nor interferes with blood levels of immunosuppressants[20]. However, it has been reported that repeated cycles of oxaliplatin in patients with prior renal impairment may cause deterioration of kidney function[22]. In our case, the kidney graft function before FOLFOX-4 initiation was already impaired (eGFR 45 mL/min/1.73 m2), but it rapidly deteriorated during the first 2 mo of therapy. However, it might have been caused by active chronic rejection coexisting with recurrent glomerulonephritis, which probably started earlier, as indicated by the previously slowly increasing serum creatinine concentration. Moreover, both processes mentioned above might be accelerated by decreasing net immunosuppression strength caused by modification of the immunosuppressive regimen and impaired drug absorption after hemicolectomy. Nevertheless, although reducing immunosuppression treatment with or without conversion to mammalian target of rapamycin inhibitor is suggested in KDIGO guidelines[15] and the literature[7,23], the risk of graft rejection and loss is not to be disregarded.

**CONCLUSION**

Several risk factors, including long-lasting immunosuppression, may contribute to CRC development in KTRs at a younger age. We acknowledge the risk of rapid kidney graft loss, which occurred during the initiation of adjuvant chemotherapy for colon cancer, but it may rather be a consequence of under-immunosuppression due to both impaired drug absorption and treatment changes driven by the cancer diagnosis. Hence, any modification of immunosuppressive regimen in newly diagnosed cancer patients should be carefully considered to balance the potential risks and benefits, bearing in mind the kidney graft function.

**REFERENCES**

1 **Argilés G**, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, Yoshino T, Taieb J, Martinelli E, Arnold D; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2020; **31**: 1291-1305 [PMID: 32702383 DOI: 10.1016/j.annonc.2020.06.022]

2 **Pendón-Ruiz de Mier V**, Navarro Cabello MD, Martínez Vaquera S, Lopez-Andreu M, Aguera Morales ML, Rodriguez-Benot A, Aljama Garcia P. Incidence and Long-Term Prognosis of Cancer After Kidney Transplantation. *Transplant Proc* 2015; **47**: 2618-2621 [PMID: 26680052 DOI: 10.1016/j.transproceed.2015.08.043]

3 **Ju MK**, Joo DJ, Kim SJ, Huh KH, Kim MS, Jeon KO, Kim HJ, Kim SI, Kim YS. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience. *Transpl Int* 2009; **22**: 644-653 [PMID: 19220824 DOI: 10.1111/j.1432-2277.2009.00846.x]

4 **Andrés A**. Cancer incidence after immunosuppressive treatment following kidney transplantation. *Crit Rev Oncol Hematol* 2005; **56**: 71-85 [PMID: 15978827 DOI: 10.1016/j.critrevonc.2004.11.010]

5 **Kim JY**, Ju MK, Kim MS, Kim NK, Sohn SK, Kim SI, Kim YS. Clinical characteristics and treatment outcomes of colorectal cancer in renal transplant recipients in Korea. *Yonsei Med J* 2011; **52**: 454-462 [PMID: 21488188 DOI: 10.3349/ymj.2011.52.3.454]

6 **Merchea A**, Abdelsattar ZM, Taner T, Dean PG, Colibaseanu DT, Larson DW, Dozois EJ. Outcomes of colorectal cancer arising in solid organ transplant recipients. *J Gastrointest Surg* 2014; **18**: 599-604 [PMID: 24254836 DOI: 10.1007/s11605-013-2402-3]

7 **Au E**, Wong G, Chapman JR. Cancer in kidney transplant recipients. *Nat Rev Nephrol* 2018; **14**: 508-520 [PMID: 29802400 DOI: 10.1038/s41581-018-0022-6]

8 **Au EH**, Chapman JR, Craig JC, Lim WH, Teixeira-Pinto A, Ullah S, McDonald S, Wong G. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. *J Am Soc Nephrol* 2019 [PMID: 30765426 DOI: 10.1681/ASN.2018090906]

9 **Papaconstantinou HT**, Sklow B, Hanaway MJ, Gross TG, Beebe TM, Trofe J, Alloway RR, Woodle ES, Buell JF. Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. *Dis Colon Rectum* 2004; **47**: 1898-1903 [PMID: 15622583 DOI: 10.1007/s10350-004-0674-0]

10 **Johnson EE**, Leverson GE, Pirsch JD, Heise CP. A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. *J Gastrointest Surg* 2007; **11**: 272-279 [PMID: 17458597 DOI: 10.1007/s11605-007-0084-4]

11 **Privitera F**, Gioco R, Civit AI, Corona D, Cremona S, Puzzo L, Costa S, Trama G, Mauceri F, Cardella A, Sangiorgio G, Nania R, Veroux P, Veroux M. Colorectal Cancer after Kidney Transplantation: A Screening Colonoscopy Case-Control Study. *Biomedicines* 2021; **9** [PMID: 34440142 DOI: 10.3390/biomedicines9080937]

12 **Webster AC**, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. *Am J Transplant* 2007; **7**: 2140-2151 [PMID: 17640312 DOI: 10.1111/j.1600-6143.2007.01908.x]

13 **Hibberd AD**, Trevillian PR, Wlodarczyk JH, Kemp DG, Stein AM, Gillies AH, Heer MK, Sheil AG. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study. *Transplantation* 2013; **95**: 122-127 [PMID: 23238532 DOI: 10.1097/TP.0b013e3182782f59]

14 **Au EH**, Wong G, Howard K, Chapman JR, Castells A, Roger SD, Bourke MJ, Macaskill P, Turner R, Lim WH, Lok CE, Diekmann F, Cross N, Sen S, Allen RD, Chadban SJ, Pollock CA, Tong A, Teixeira-Pinto A, Yang JY, Kieu A, James L, Craig JC. Factors Associated With Advanced Colorectal Neoplasia in Patients With CKD. *Am J Kidney Dis* 2022; **79**: 549-560 [PMID: 34461168 DOI: 10.1053/j.ajkd.2021.07.011]

15 **Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group**. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant* 2009; **9 Suppl 3**: S1-155 [PMID: 19845597 DOI: 10.1111/j.1600-6143.2009.02834.x]

16 **Collins MG**, Teo E, Cole SR, Chan CY, McDonald SP, Russ GR, Young GP, Bampton PA, Coates PT. Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy. *BMJ* 2012; **345**: e4657 [PMID: 22833618 DOI: 10.1136/bmj.e4657]

17 **Wong G**, Howard K, Craig JC, Chapman JR. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. *Transplantation* 2008; **85**: 532-541 [PMID: 18347531 DOI: 10.1097/TP.0b013e3181639d35]

18 **Auge JM**, Pellise M, Escudero JM, Hernandez C, Andreu M, Grau J, Buron A, López-Cerón M, Bessa X, Serradesanferm A, Piracés M, Macià F, Guayta R, Filella X, Molina R, Jimenez W, Castells A; PROCOLON Group. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. *Gastroenterology* 2014; **147**: 628-636.e1 [PMID: 24937264 DOI: 10.1053/j.gastro.2014.06.008]

19 **Bellyei S**, Boronkai Á, Pozsgai E, Fodor D, Mangel L. Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report. *J Med Case Rep* 2021; **15**: 125 [PMID: 33741057 DOI: 10.1186/s13256-021-02702-y]

20 **Fang W**. Chemotherapy in patient with colon cancer after renal transplantation: A case report with literature review. *Medicine (Baltimore)* 2018; **97**: e9678 [PMID: 29384845 DOI: 10.1097/MD.0000000000009678]

21 **Haller DG**. Safety of oxaliplatin in the treatment of colorectal cancer. *Oncology (Williston Park)* 2000; **14**: 15-20 [PMID: 11204657]

22 **Kawazoe H**, Kawazoe H, Sugishita H, Watanabe S, Tanaka A, Morioka J, Suemaru K, Watanabe Y, Kawachi K, Araki H. [Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. *Gan To Kagaku Ryoho* 2010; **37:** 1153-1157 [PMID: 20567127]

23 **Alberú J**. Clinical insights for cancer outcomes in renal transplant patients. *Transplant Proc* 2010; **42**: S36-S40 [PMID: 21095450 DOI: 10.1016/j.transproceed.2010.07.006]

24 **Liu HY**, Liang XB, Li YP, Feng Y, Liu DB, Wang WD. Treatment of advanced rectal cancer after renal transplantation. *World J Gastroenterol* 2011; **17**: 2058-2060 [PMID: 21528088 DOI: 10.3748/wjg.v17.i15.2058]

25 **Xia Z**, Chen W, Yao R, Lin G, Qiu H. Laparoscopic assisted low anterior resection for advanced rectal cancer in a kidney transplant recipient: A case report. *Medicine (Baltimore)* 2016; **95**: e5198 [PMID: 27858861 DOI: 10.1097/MD.0000000000005198]

26 **Müsri FY**, Mutlu H, Eryılmaz MK, Salim DK, Coşkun HŞ. Experience of bevacizumab in a patient with colorectal cancer after renal transplantation. *J Cancer Res Ther* 2015; **11**: 1018-1020 [PMID: 26881574 DOI: 10.4103/0973-1482.168996]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 14, 2021

**First decision:** February 14, 2022

**Article in press:** April 22, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Poland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Gadelkareem RA, Egypt; Kaewput W, Thailand; Kiuchi J, Japan; Singh N, United States **S-Editor:** Fan JR **L-Editor:** Kerr C **P-Editor:** Fan JR


**Figure Legends**



**Figure 1 Changes in the immunosuppression therapy after hemicolectomy and diagnosis of colon cancer.**



**Figure 2 Pathological findings in transplanted kidney biopsy.** A and B: Glomerulus with segmental sclerosis – black arrow (A) – and reactive proliferation of podocytes around sclerosed segment – orange arrow (B); C and D: Area of tubular atrophy – black arrow – and compensative tubular hypertrophy – asterisks (C), with areas of interstitial fibrosis with infiltration of mononuclear cells – orange arrows (D); E–H: Immunohistochemistry showing focal interstitial infiltrates mainly composed of CD4-positive (E) and CD20-positive (G) cells, and diffuse interstitial infiltrates of CD8-positive (F) and CD68-positive (H) cells.



**Figure 3 Pathological intraperitoneal infiltration (arrows) measuring 83 mm × 46 mm × 52 mm, with a standardized maximum uptake of 8.5 located in the right epigastric region, shown in computed tomography (A) and positron emission tomography (B) examinations.**

**Table 1 Timeline of diagnostic procedures and treatment**

|  |  |
| --- | --- |
| **Date** | **Procedure** |
| 1994 | Diagnosis of glomerular nephritis (kidney biopsy) |
| 1994 | Therapy with glucocorticoids and cyclophosphamide |
| 2004 | Initiation of hemodialysis therapy |
| 2005 | Kidney transplantation |
| October 2020 | Recurrent abdominal pain |
| January 26, 2021 | Right hemicolectomy |
| February 2021 | Initiation of adjuvant chemotherapy (FOLFOX-4) |
| February 25, 2021 | Abdominal laceration abscess surgery |
| March 17 to 19, 2021 | 1st FOLFOX-4 |
| April 1, 2021 | 2nd FOLFOX-4 |
| April 19, 2021 | Postponement of chemotherapy |
| May 5, 2021 | Postponement of chemotherapy |
| May 14, 2021 | Adjuvant chemotherapy termination |
| June 1, 2021 | Kidney graft biopsy |
| June 17, 2021 | First CT of the abdomen and pelvis |
| September 30, 2021 | Second CT of the abdomen and pelvis |
| October 28, 2021 | Surgical creation of an arteriovenous shunt |
| October 29, 2021 | PET-CT |
| December 8, 2021 | Initiation of hemodialysis therapy |
| December 21, 2021 | Initiation of palliative chemotherapy (FOLFOX-4) |

CT: Computed tomography; PET–CT: Positron emission tomography–computed tomography.

**Table 2 Clinical characteristics of kidney transplant patients treated with adjuvant (*n* = 7) and palliative chemotherapy (*n* = 5) for colorectal cancer**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Refs** | **Patients** | **Sex** | **Age at diagnosis, yr** | **Clinical stage** | **Chemotherapy** | **Cycles** | **Graft loss** | **ADR** | **Response** | **DFS/PFS (mo)** | **OS (mo)** |
| Kim *et al*[5] | 5 of 171 | 6 W, 11 M | 54 ± 7 | Stage 0 (*n* = 2) |  |  | Yes, 2 (within 1 yr) |  |  | 25.1 ± 9.2 |  |
| Stage I (*n* = 5) |  |  |  |  |  |  |  |
| Stage II (*n* = 3) | FU-LV (*n* = 1) | 12 |  | NS |  |  | NA |
| Stage III (*n* = 3) | Capecitabine (*n* = 2) | 12 |  | NS |  |  | 25 |
| Stage IV (*n* = 4) | Capecitabine (*n* = 1); FU-LV (*n* = 1) | 8  12 |  | NS |  |  | 10 |
| Fang[20] | 1 | M | 36 | Stage II (pT3N0M0) | FOLFOX | 3 | No | NS | PD | 0 | NA |
| Liu *et al*[24] | 2 | M | 44 | Stage II (pT3N0M0) | Capecitabine | 8 | No | NA | SD | NA | Alive after 21 |
| M | 54 | Stage II (pT3N0M0) | Capecitabine | 8 | No | NA | SD | NA | Alive after 8 |
| Xia *et al*[25] | 1 | M | 51 | Stage III B (pT3N1M0) | FOLFOX | 8 | No | NS | PR | NA | NA |
| Liu *et al*[24] | 1 | M | 68 | Stage III (pT4N1M0) | Capecitabine (after progression) | 3 | No | NS | PR | 2 | 4-5 for CTH |
| Müsri *et al*[26] | 1 | M | 64 | Stage IV | FOLFIRI + bevacizumab | 5 | NS | Proteinuria | PR (regression of liver metastasis) | NA | NA |
| Deterioration of kidney function |
| Bellyei *et al*[19] | 1 | M | 66 | Stage IV | FOLFIRI + cetuximab | 1 | No | Blood sugar level fluctuation | NA | NA | NA |
|  |  |  |  |  |  |  |  | Diarrhea |  |  |  |
|  |  |  |  |  |  |  |  | Hypomagnesemia |  |  |  |
|  |  |  |  |  | FOLFIRI + panitumumab | 3 | No | Weight loss | PR  (paraaortic lymph node regression) | NA | NA |
|  |  |  |  |  |  |  |  | Diarrhea |  |  |  |
|  |  |  |  |  |  |  |  | Hypomagnesemia |  |  |  |
|  |  |  |  |  | SBRT + panitumumab | 16 | No | Skin rash | CR | NA | NA-stroke |
|  |  |  |  |  |  |  |  | Hypomagnesemia |  |  |  |

1Characteristics and outcome data for 17 patients cohort, including 5 patients that received CTH.

M: Man; W: Women; ADR: Adverse drug reaction; DSF: Disease-free survival; PFS: Progression-free survival, OS: Overall survival; NS: Not specified; NA: Not available; FU-LV: 5-flurouracil-leucovorin; PD: Progressive disease; SD: Stable disease; PR: Partial Response; SBRT: Stereotactic body irradiation; CR: Complete response.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**